Related Experiment Videos
Circulating biomarkers for lung cancer
1Azienda Ospedaliera S. Croce e Carle, Divisione di Pneumologia, Cuneo, Italy.
Annali Italiani Di Chirurgia
|May 11, 2000
Summary
Tumor markers are not efficient for lung cancer screening but can aid diagnosis when pathologically elevated. They help evaluate disease extent, prognosis, and monitor treatment effectiveness post-surgery.
Area of Science:
- Oncology
- Clinical Diagnostics
- Biomarker Research
Background:
- Tumor markers are crucial in cancer management.
- Understanding their ideal characteristics is key for clinical application.
- Current roles in screening, diagnosis, and monitoring require evaluation.
Purpose of the Study:
- To discuss the ideal characteristics of tumor markers.
- To evaluate the role of tumor markers in clinical practice, including screening, diagnosis, and monitoring.
- To assess the utility of specific markers like CEA, NSE, and TPA in lung cancer.
Main Methods:
- Literature review and discussion of existing data on tumor marker utility.
- Analysis of the diagnostic and prognostic value of tumor markers in lung cancer.
- Evaluation of tumor markers for disease extent assessment and therapy monitoring.
Main Results:
- Tumor marker measurement in screening programs is inefficient.
- Pathological elevation of markers can be diagnostic for lung cancer in specific contexts.
- Elevated CEA, NSE, and TPA are useful for assessing disease extent and prognosis.
Conclusions:
- Tumor markers are not suitable for general lung cancer screening.
- Their elevated levels are valuable for diagnosis in appropriate clinical settings.
- Markers aid in evaluating disease extent, prognosis, and post-surgical monitoring.